Nine Thousand People Register For The COVID-19 Vaccine Clinical Trials In Brazil

JAKARTA - Brazil has agreed to become a clinical trial country for a potential coronavirus vaccine that is being developed by Sinovac China, a biotech company from the Bamboo Curtain country. One of Brazil's health policy regulators, Anvisa has announced this news live.

According to Reuters, prior to the clinical trial agreement, Sinovac China and Brazil had conducted joint studies on a potential vaccine since June 11. The study was led by the Instituto Butantan, a research center funded by the State of Sao Paulo.

The agreement between Brazil and Sinovac itself includes not only trials, but also transfers of technology needed to produce a potential vaccine locally. Later clinical trials will be carried out in 12 research centers in six states in Brazil.

The six states are Sao Paulo, Rio de Janeiro, Minas Gerais, Brasilia, Rio Grande do Sul, and Parana. On June 29, the Governor of the State of Sao Paulo Joao Dorla said that nine thousand volunteers had registered for the clinical trial plan.

Cooperation between Brazil and Sinovac China was forged when the COVID-19 cases in Samba Country exceeded the 1.5 million mark. According to data from the Ministry of Health, Brazil is the country worst hit by COVID-19 after the United States (US).

The number of deaths in Brazil has risen to 1,290 in the last 24 hours. With that figure, the total deaths from COVID-19 in Brazil will be 63,174.